<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01780454</url>
  </required_header>
  <id_info>
    <org_study_id>2013P000822</org_study_id>
    <nct_id>NCT01780454</nct_id>
  </id_info>
  <brief_title>Renal Allograft Tolerance Through Mixed Chimerism</brief_title>
  <official_title>Renal Allograft Tolerance Through Mixed Chimerism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and effectiveness of a combination kidney and bone marrow&#xD;
      transplant from a haplo-identical related donor. An investigational medication and other&#xD;
      treatments will be given prior to and after the transplant to help protect the transplanted&#xD;
      kidney from being attacked by the body's immune system&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Withdrawal of Immunosuppressive Therapy</measure>
    <time_frame>5 years</time_frame>
    <description>The primary endpoint is induction of transient mixed chimerism and renal allograft tolerance without &quot;engraftment syndrome&quot; or &quot;acute kidney injury&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Engraftment Syndrome</measure>
    <time_frame>5 Years</time_frame>
    <description>Constellation of symptoms known &quot;Engraftment Syndrome&quot;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-507</intervention_name>
    <description>T-Cell Depleting Agent</description>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>B-Cell Depleting Agent</description>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>Bone Marrow Depletion</description>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thymic Irradiation</intervention_name>
    <arm_group_label>Combined Bone Marrow and Kidney Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18-60 years of age&#xD;
&#xD;
          -  Candidate for a living-donor renal allograft with a one haplotype identical donor&#xD;
             identified.&#xD;
&#xD;
          -  First or second transplant with either a living donor or cadaveric transplant as the&#xD;
             first transplant.&#xD;
&#xD;
          -  Positive serologic testing for EBV indicating past exposure.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  ABO blood group-incompatible renal allograft.&#xD;
&#xD;
          -  Evidence of anti-HLA antibody within 60 days prior to transplant as assessed by&#xD;
             routine methodology (AHG and/or ELISA)&#xD;
&#xD;
          -  Positive testing for: HIV, hepatitis B core antigen, or hepatitis C virus or&#xD;
             positivity for hepatitis B surface antigen.&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 40% or clinical evidence of insufficiency.&#xD;
&#xD;
          -  History of cancer other than basal cell carcinoma of the skin or carcinoma in situ of&#xD;
             the cervix.&#xD;
&#xD;
          -  Underlying renal disease etiology with a high risk of disease recurrence in the&#xD;
             transplanted kidney (such as focal segmental glomerulosclerosis, type I or II&#xD;
             nonproliferative glomerulonephritis).&#xD;
&#xD;
          -  Prior dose-limiting radiation therapy.&#xD;
&#xD;
          -  Abnormal (&gt;2 times lab normal) values for (a) liver function chemistries (ALT, AST,&#xD;
             AP), (b) bilirubin, (c) coagulation studies (PT, PTT).&#xD;
&#xD;
          -  The presence of any medical condition that the investigator deems incompatible with&#xD;
             participation in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Benedict Cosimi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Sachs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kawai T, Cosimi AB, Sachs DH. Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant. 2011 Aug;16(4):366-71. doi: 10.1097/MOT.0b013e3283484b2c. Review.</citation>
    <PMID>21666482</PMID>
  </reference>
  <reference>
    <citation>Sachs DH, Sykes M, Kawai T, Cosimi AB. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol. 2011 Jun;23(3):165-73. doi: 10.1016/j.smim.2011.07.001. Epub 2011 Aug 11. Review.</citation>
    <PMID>21839648</PMID>
  </reference>
  <reference>
    <citation>Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FI, Ding R, Sharma V, Fishman JA, Dey B, Ko DS, Hertl M, Goes NB, Wong W, Williams WW Jr, Colvin RB, Sykes M, Sachs DH. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008 Jan 24;358(4):353-61. doi: 10.1056/NEJMoa071074.</citation>
    <PMID>18216355</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 29, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2013</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2020</results_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David Sachs M.D.</investigator_full_name>
    <investigator_title>Director, Transplantation Biology Research Center</investigator_title>
  </responsible_party>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Renal Transplant</keyword>
  <keyword>Bone Marrow Transplant</keyword>
  <keyword>Tolerance</keyword>
  <keyword>Chimerism</keyword>
  <keyword>ESRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT01780454/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combined Bone Marrow and Kidney Transplantation</title>
          <description>Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation&#xD;
MEDI-507: T-Cell Depleting Agent&#xD;
Rituximab: B-Cell Depleting Agent&#xD;
Total Body Irradiation: Bone Marrow Depletion&#xD;
Thymic Irradiation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combined Bone Marrow and Kidney Transplantation</title>
          <description>Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation&#xD;
MEDI-507: T-Cell Depleting Agent&#xD;
Rituximab: B-Cell Depleting Agent&#xD;
Total Body Irradiation: Bone Marrow Depletion&#xD;
Thymic Irradiation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Withdrawal of Immunosuppressive Therapy</title>
        <description>The primary endpoint is induction of transient mixed chimerism and renal allograft tolerance without &quot;engraftment syndrome&quot; or &quot;acute kidney injury&quot;</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combined Bone Marrow and Kidney Transplantation</title>
            <description>Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation&#xD;
MEDI-507: T-Cell Depleting Agent&#xD;
Rituximab: B-Cell Depleting Agent&#xD;
Total Body Irradiation: Bone Marrow Depletion&#xD;
Thymic Irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Withdrawal of Immunosuppressive Therapy</title>
          <description>The primary endpoint is induction of transient mixed chimerism and renal allograft tolerance without &quot;engraftment syndrome&quot; or &quot;acute kidney injury&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Engraftment Syndrome</title>
        <description>Constellation of symptoms known &quot;Engraftment Syndrome&quot;</description>
        <time_frame>5 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combined Bone Marrow and Kidney Transplantation</title>
            <description>Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation&#xD;
MEDI-507: T-Cell Depleting Agent&#xD;
Rituximab: B-Cell Depleting Agent&#xD;
Total Body Irradiation: Bone Marrow Depletion&#xD;
Thymic Irradiation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Engraftment Syndrome</title>
          <description>Constellation of symptoms known &quot;Engraftment Syndrome&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Combined Bone Marrow and Kidney Transplantation</title>
          <description>Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation&#xD;
MEDI-507: T-Cell Depleting Agent&#xD;
Rituximab: B-Cell Depleting Agent&#xD;
Total Body Irradiation: Bone Marrow Depletion&#xD;
Thymic Irradiation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Sachs</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-4065</phone>
      <email>David.Sachs@tbrc.mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

